Salud financiera de hoja de balance de BioMarin Pharmaceutical
Salud financiera controles de criterios 6/6
BioMarin Pharmaceutical tiene un patrimonio de accionistas total de $5.4B y una deuda total de $594.6M, lo que sitúa su ratio deuda-patrimonio en 11%. Sus activos y pasivos totales son $6.9B y $1.4B respectivamente. El BAIT de BioMarin Pharmaceutical es de $326.4M, por lo que su ratio de cobertura de intereses es de -5.5. Tiene efectivo e inversiones a corto plazo que ascienden a $930.4M.
Información clave
11.0%
Ratio deuda-patrimonio
US$594.63m
Deuda
| Ratio de cobertura de intereses | -5.5x |
| Efectivo | US$930.44m |
| Patrimonio | US$5.41b |
| Total pasivo | US$1.44b |
| Activos totales | US$6.85b |
Actualizaciones recientes sobre salud financiera
BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Recent updates
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar
Nov 14BioMarin Pharmaceutical (NASDAQ:BMRN) Seems To Use Debt Rather Sparingly
Sep 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued
Jun 01BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($3.1B) de BMRN superan a sus pasivos a corto plazo ($715.7M).
Pasivo a largo plazo: Los activos a corto plazo de BMRN ($3.1B) superan a sus pasivos a largo plazo ($722.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BMRN tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de BMRN ha pasado de 27.4% a 11% en los últimos 5 años.
Cobertura de la deuda: La deuda de BMRN está bien cubierta por el flujo de caja operativo (69.7%).
Cobertura de intereses: BMRN gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.